Device type · LEG
Enzyme Immunoassay, Valproic Acid
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
LEG
Clinical Toxicology
Device class
Class II
FDA decisions since 2015
0
510(k), De Novo and PMA
Adverse event reports
8
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Enzyme Immunoassay, Valproic Acid
- Product code
- LEG
- Device class
- Class II
- Review panel
- Clinical Toxicology
- Regulation
- 21 CFR 862.3645
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for LEG
Latest FDA decisions
No 510(k), De Novo or PMA decisions for this product code since 2015.
Reports received
8
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
8
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 3 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 1 | 0 | 0 | 0 |
| Jun 24 | 1 | 0 | 0 | 0 |
| Jul 24 | 2 | 0 | 0 | 0 |
| Aug 24 | 2 | 0 | 0 | 0 |
| Sep 24 | 2 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 1 | 0 | 0 | 0 |
| Dec 24 | 2 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 1 | 0 | 0 | 0 |
| May 25 | 1 | 0 | 0 | 0 |
| Jun 25 | 1 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 1 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 1 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 3 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 2 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 2 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- Low Test Results5
- High Test Results2
- Incorrect Measurement1
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions8
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0848-2019 · Started Dec 11, 2018
Reason given: Negative bias results when using VITROS VALP Reagent, GEN 25.
Cause as FDA categorized it: Process control
Z-0984-2012 · Started May 10, 2011 · Posted by FDA Feb 8, 2012
Reason given: Results using VITROS Chemistry Products VALP Reagent were negatively biased compared to other manufacturers. OCD confirmed that patient results were also affected by this issue.
Cause as FDA categorized it: Manufacturing material removal
Z-0920-2007 · Started Apr 30, 2007 · Posted by FDA Jun 9, 2007
Reason given: Probe Wash: Reported results may have a positive bias because inadequate analyzer probe wash instructions may result in carry-over from the following assays: Creatinine Kinase L and Creatine Kinase-MBL.
Cause as FDA categorized it: Other
Bayer Healthcare, LLC (Diagnostics Division)
Z-0351-2007 · Started Sep 8, 2006 · Posted by FDA Jan 17, 2007
Reason given: Bayer received a customer complaint where the Valproic Acid Quality control material recovered lower than target when it was run in a panel of other Therapeutic Drug (TDM) assays. The under recovery observed by the customer was approximately -25%.
Cause as FDA categorized it: Software design
Bayer Healthcare, LLC (Diagnostics Division)
Z-0352-2007 · Started Sep 8, 2006 · Posted by FDA Jan 17, 2007
Reason given: Bayer received a customer complaint where the Valproic Acid Quality control material recovered lower than target when it was run in a panel of other Therapeutic Drug (TDM) assays. The under recovery observed by the customer was approximately -25%. Investigation into this issue was initiated promptly following receipt...
Cause as FDA categorized it: Software design
Bayer Healthcare, LLC (Diagnostics Division)
Z-0353-2007 · Started Sep 8, 2006 · Posted by FDA Jan 17, 2007
Reason given: Bayer received a customer complaint where the Valproic Acid Quality control material recovered lower than target when it was run in a panel of other Therapeutic Drug (TDM) assays. The under recovery observed by the customer was approximately -25%. Investigation into this issue was initiated promptly following receipt...
Cause as FDA categorized it: Software design
Z-0866-05 · Started Apr 18, 2005 · Posted by FDA Jun 4, 2005
Reason given: Negatively biased results may be observed when the reagent is stored on the VITROS 5,1FS Chemistry System for less than seven days.
Cause as FDA categorized it: Other
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.